Merck restructures its Human Health business as Keytruda faces a 2028 patent loss. Merck & Co. Inc. (NYSE:MRK) shares are up during Monday’s premarket session as the company is evolving its Human...
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines. Merck said on Monday it will split its human-he...
Merck said on Monday it will split its human-health business into two divisions, separating its blockbuster cancer franchise led by Keytruda from its non-oncology medicines. The shake-up comes as the ...
Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug has impacted its business. Merck could still be a winning stock, despite the...
US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, h...
US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, h...
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday. Merck now expects mid-term an...
